Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...
Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.
GlobalData on MSN1d
Alphamab doses first subject in trial of JSKN003 for ovarian cancerAlphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...
SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- On December 19, 2024, BioRay Pharmaceutical Co., Ltd ... BR111 is an antibody-drug conjugate (ADC) targeting dual epitopes of ROR1, intended for the ...
BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed Class 1 innovative ...
Asian News International on MSN2d
Jubilant Biosys Limited Seals Deal With Pierre Fabre SANoida, Uttar Pradesh, India <li /> To acquire R&D center at Saint-Julien-en-Genevois, France <li /> To add Drug Discovery & Preclin ...
This acquisition marks a significant step in Jubilant Biosys' global strategy, providing a foothold in Europe's expanding ...
Axplora, a German CDMO that specializes in API small molecule and ADC production, will upgrade its manufacturing facility in ...
Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects ...
From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback